Barclays Maintains HCA Healthcare(HCA.US) With Buy Rating, Cuts Target Price to $392

巴克萊銀行維持HCA醫療(HCA.US)買入評級，下調目標價至392美元

moomoo資訊 · 11/08 19:35 · 評級/大行評級

Barclays analyst Andrew Mok CFA maintains $HCA Healthcare (HCA.US)$ with a buy rating, and adjusts the target price from $396 to $392.

According to TipRanks data, the analyst has a success rate of 42.1% and a total average return of -5.4% over the past year.

AnalystRecentRatingAutoNews_206673_20241108_895a75317c6ce2edded518f023d220daf61922b7_1731144685645665_mm_en

Furthermore, according to the comprehensive report, the opinions of $HCA Healthcare (HCA.US)$'s main analysts recently are as follows:

The previous year was exceptionally favorable for the hospital sector, and the outlook for the upcoming year continues to be promising, presenting potential for earnings growth for both HCA Healthcare and Tenet based on realistic projections for organic expansion.
Following Q3 earnings, there is an update to models and detailed earnings projections for each hospital. The core revisions are generally minor; however, adjustments are made to account for the effects of hurricanes and updated assumptions regarding Medicaid supplemental payments.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

巴克萊銀行分析師Andrew Mok CFA維持$HCA醫療 (HCA.US)$買入評級，並將目標價從396美元下調至392美元。

根據TipRanks數據顯示，該分析師近一年總勝率為42.1%，總平均回報率為-5.4%。

AnalystRecentRatingAutoNews_206673_20241108_895a75317c6ce2edded518f023d220daf61922b7_1731144685645665_mm_tc

此外，綜合報道，$HCA醫療 (HCA.US)$近期主要分析師觀點如下：

去年的醫院行業異常有利，來年的前景仍然令人鼓舞，根據對有機擴張的現實預測，HCA Healthcare和Tenet的盈利增長潛力。
繼第三季度業績之後，將對每家醫院的模型和詳細的收益預測進行更新。核心修訂通常很小；但是，進行了調整以考慮颶風的影響以及有關醫療補助補充補助金的最新假設。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Barclays Maintains HCA Healthcare(HCA.US) With Buy Rating, Cuts Target Price to $392

Barclays Maintains HCA Healthcare(HCA.US) With Buy Rating, Cuts Target Price to $392

風險及免責聲明

聲明